The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127(1):e6-e245
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106(24):3068-72
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69
   PubMed Web of Science ®Google Scholar
• Struthers AD. Pathophysiology of heart failure following myocardial infarction. Heart 2005;91(Suppl 2):ii14-16. discussion ii31, ii43-8
   PubMedGoogle Scholar
• Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 2004(5 Suppl 1):S7-10
   PubMed Web of Science ®Google Scholar
• Schroten NF, Gaillard CA, van Veldhuisen DJ, et al. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev 2012;17(2):191-201
   PubMed Web of Science ®Google Scholar
• Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33(9):1058-66
   PubMed Web of Science ®Google Scholar
• Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91(11):988-98
   PubMed Web of Science ®Google Scholar
• Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160(6):1273-92
   PubMed Web of Science ®Google Scholar
• Clark AL, Cleland JG. The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev 2000;5(1):101-14
   PubMedGoogle Scholar
• Bradshaw PJ, Stobie P, Briffa T, Hobbs MS. Use and long-term outcomes of implantable cardioverter-defibrillators, 1990 to 2009. Am Heart J 2013;165(5):816-22
   PubMed Web of Science ®Google Scholar
• Kandala J, Upadhyay GA, Altman RK, et al. QRS morphology, left ventricular lead location, and clinical outcome in patients receiving cardiac resynchronization therapy. Eur Heart J 2013;34(29):2252-62
   PubMed Web of Science ®Google Scholar
• Ross JS, Chen J, Lin Z, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010;3(1):97-103
   PubMed Web of Science ®Google Scholar
• Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013;34(19):1424-31
   PubMed Web of Science ®Google Scholar
• Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail 2013;6(2):279-86
   PubMed Web of Science ®Google Scholar
• Chaudhry SI, McAvay G, Chen S, et al. Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. J Am Coll Cardiol 2013;61(6):635-42
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251-9
   PubMed Web of Science ®Google Scholar
• Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43(3):317-27
   PubMed Web of Science ®Google Scholar
• Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358(20):2148-59
   PubMed Web of Science ®Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113(19):2335-62
   PubMed Web of Science ®Google Scholar
• Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005;20(3):201-10
   PubMed Web of Science ®Google Scholar
• de Virginy DR. Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure: a clinical review. Heart Fail Rev 2006;11(4):333-4
   PubMed Web of Science ®Google Scholar
• Lainscak M, von Haehling S, Springer J, Anker SD. Biomarkers for chronic heart failure. Heart Fail Monit 2007;5(3):77-82
   PubMedGoogle Scholar
• Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med 2008;46(6):748-63
   PubMed Web of Science ®Google Scholar
• Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49(16):1733-9
   PubMed Web of Science ®Google Scholar
• Gaggin HK, Mohammed AA, Bhardwaj A, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 2012;18(8):626-34
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013;127(4):500-7. discussion 508
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep 2013;15(6):372
   PubMed Web of Science ®Google Scholar
• de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11(9):811-17
   PubMed Web of Science ®Google Scholar
• Raimond J, Zimonjic DB, Mignon C, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome 1997;8(9):706-7
   PubMed Web of Science ®Google Scholar
• Henrick K, Bawumia S, Barboni EA, et al. Evidence for subsites in the galectins involved in sugar binding at the nonreducing end of the central galactose of oligosaccharide ligands: sequence analysis, homology modeling and mutagenesis studies of hamster galectin-3. Glycobiology 1998;8(1):45-57
   PubMed Web of Science ®Google Scholar
• Seetharaman J, Kanigsberg A, Slaaby R, et al. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998;273(21):13047-52
   PubMed Web of Science ®Google Scholar
• Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110(19):3121-8
   PubMed Web of Science ®Google Scholar
• Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013;6(1):107-17
   PubMed Web of Science ®Google Scholar
• Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006;103(13):5060-5
   PubMed Web of Science ®Google Scholar
• Cao Z, Said N, Amin S, et al. Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds. J Biol Chem 2002;277(44):42299-305
   PubMed Web of Science ®Google Scholar
• Pacis RA, Pilat MJ, Pienta KJ, et al. Decreased galectin-3 expression in prostate cancer. Prostate 2000;44(2):118-23
   PubMed Web of Science ®Google Scholar
• Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127(11):2530-41
   PubMed Web of Science ®Google Scholar
• Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31(4):277-85
   PubMed Web of Science ®Google Scholar
• Hattasch R, Spethmann S, de Boer RA, et al. Galectin-3 increase in endurance athletes. Eur J Prev Cardiol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230(1):160-71
   PubMed Web of Science ®Google Scholar
• Hartupee J, Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res 2013;6(4):485-92
   PubMed Web of Science ®Google Scholar
• Szadkowska I, Wlazel RN, Migala M, et al. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172(2):288-98
   PubMed Web of Science ®Google Scholar
• Azibani F, Benard L, Schlossarek S, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012;59(6):1179-87
   PubMed Web of Science ®Google Scholar
• Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33(1):67-75
   PubMed Web of Science ®Google Scholar
• Martin R, Miana M, Jurado-Lopez R, et al. DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. PLoS One 2012;7(7):e41545
   PubMed Web of Science ®Google Scholar
• Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008;294(3):H1226-32
   PubMed Web of Science ®Google Scholar
• Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60(14):1249-56
   PubMed Web of Science ®Google Scholar
• de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272(1):55-64
   PubMed Web of Science ®Google Scholar
• van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48(6):1217-24
   PubMed Web of Science ®Google Scholar
• van der Velde AR, Gullestad L, Ueland T, et al. Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: data From CORONA and COACH. Circ Heart Fail 2013;6(2):219-26
   PubMed Web of Science ®Google Scholar
• de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43(1):60-8
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12(8):826-32
   PubMed Web of Science ®Google Scholar
• de Boer RA, Edelmann F, Cohen-Solal A, et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15(10):1095-101
   PubMed Web of Science ®Google Scholar
• Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99(5):323-8
   PubMed Web of Science ®Google Scholar
• Ueland T, Aukrust P, Broch K, et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011;150(3):361-4
   PubMed Web of Science ®Google Scholar
• Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108(3):385-90
   PubMed Web of Science ®Google Scholar
• Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012;164(6):878-83
   PubMed Web of Science ®Google Scholar
• Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012;5(1):72-8
   PubMed Web of Science ®Google Scholar
• Anand IS, Rector TS, Kuskowski M, et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013;15(5):511-18
   PubMed Web of Science ®Google Scholar
• Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008;27(6):589-96
   PubMed Web of Science ®Google Scholar
• de Boer RA, Wanner C, Blouin K, Drechsler C. Abstract 11743: galectin-3 and outcomes in patients with end-stage renal disease: data from the german diabetes and dialysis study. Circulation 2011;124:A11743
   Google Scholar
• Christenson RH, Duh SH, Wu AH, et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010;43(7-8):683-90
   PubMed Web of Science ®Google Scholar
• BGM Galectin-3® Test. Available from: www.galectin-3.com/wp-content/uploads/2014/01/lab-0001-16-galectin-3-package-insert-us.pdf
   Google Scholar
• La’ulu SL, Apple FS, Murakami MM, et al. Performance characteristics of the ARCHITECT Galectin-3 assay. Clin Biochem 2013;46(1-2):119-22
   PubMed Web of Science ®Google Scholar
• Gaze DC, Prante C, Dreier J, et al. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Quantikine® ELISA. Available from: www.rndsystems.com/pdf/DGAL30.pdf
   Google Scholar
• Gruson D, Mancini M, Ahn SA, Rousseau MF. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2013;429C:189-93
   Google Scholar
• Tecan. Available from: www.tecan.com/page/content/index.asp?MenuID=1245&ID=661&Menu=1&Item=21
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013. [Epub ahead of print]
   Google Scholar
• Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409(1-2):96-9
   PubMed Web of Science ®Google Scholar
• Balasubramanian K, Vasudevamurthy R, Venkateshaiah SU, et al. Galectin-3 in urine of cancer patients: stage and tissue specificity. J Cancer Res Clin Oncol 2009;135(3):355-63
   PubMed Web of Science ®Google Scholar
• Lopez-Andres N, Rossignol P, Iraqi W, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012;14(1):74-81
   PubMed Web of Science ®Google Scholar
• Drechsler C, Wanner C, Blouin K, et al. An evaluation of the novel fibrosis marker galectin-3 in hemodialysis patients – results from the German diabetes dialysis study. Nephrol Dial Transplant 2013;S489
   Google Scholar
• van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin Chem 2012;58(1):127-38
   PubMed Web of Science ®Google Scholar